Trial Profile
Phase IB-II, Open Label, Multicenter Feasibility Study of Pazopanib in Combination With Paclitaxel and Carboplatin in Patients With Platinum-Refractory/Resistant Ovarian, Fallopian Tube or Peritoneal Carcinoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Bevacizumab; Carboplatin; Paclitaxel
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 14 Feb 2023 Status changed from active, no longer recruiting to completed.
- 10 Mar 2022 This trial has been completed in Spain (Global End Date 13 Jul 2020), according to European Clinical Trials Database record.
- 24 Nov 2020 This trial has been completed in Netherlands (Global End Date 13 Jul 2020), according to European Clinical Trials Database record.